7 results about "Renal Cell Cancers" patented technology

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

The application discloses a kind of kidney cell cancer patient prognosis risk prediction methods based on multi-modal deep learning.The present application processes whole field digital pathology section (WSI) image and pathological diagnosis report by deep learning algorithm, extracts text features using natural language processing model, extracts image features using computer vision model and ABMIL network, and carries out multi-modal feature fusion through Cross-attention Transformer network, and finally outputs the survival risk curve of patient changes with time in combination with Weibull survival function, for assisting doctor to carry out more accurate prognosis evaluation and survival analysis.

The present application belongs to the technical field of biological medicine, and relates to a gene therapy preparation for treating drug-resistant renal cell carcinoma as well as a preparation method and application thereof. It is found for the first time that UBL3 is a key gene for mediating cross-resistance of VEGFR inhibitors of renal cancer, and a lipid nanoparticle composite system integrating specific gene editing and active targeted delivery functions is constructed based on this. The preparation can effectively restore the sensitivity of drug-resistant tumors to first-line drugs such as sunitinib, and shows a significant anticancer effect in in-vivo and in-vitro models, and has important clinical transformation value.

The application relates to the technical field of tumor treatment, and particularly discloses application of NOSIP in preparation of a drug for treating renal cell carcinoma, and provides small interfering RNA (siRNA) for interfering with NOSIP expression, a target sequence of which is shown in SEQ ID No. 1 and / or SEQ ID No. 2. The application proves that NOSIP can promote proliferation, migration, invasion and angiogenesis of renal cell carcinoma cells, and is a key factor for driving malignant progression of renal cell carcinoma. By knocking down NOSIP expression through specific siRNA, the proliferation capacity, migration capacity, invasion capacity and angiogenesis capacity of renal cell carcinoma cells can be significantly inhibited. The application provides a new molecular target and candidate drug for treatment of renal cell carcinoma, and can be used for preparing a drug for treating renal cell carcinoma, inhibiting proliferation, migration and angiogenesis of renal cell carcinoma.

The present application relates to the technical field of renal cell carcinoma, and particularly relates to a method for predicting the lipid metabolism regulation mechanism of renal cell carcinoma, which is characterized by the following steps: determining the expression difference of EMT, cell proliferation and apoptosis proteins in groups through molecular detection, and determining the difference of fat pathway genes, oil accumulation degree and fat factor expression level in groups, and determining the correlation between lipid metabolism and GAD2, the present project first proposes the miR-metabolic enzyme-lipid pool regulation axis, which is different from the traditional mode of miR directly targeting proliferation genes. Previous studies have focused on the regulation of miRNA on directly related genes such as tumor cell proliferation and apoptosis, and the present project starts from the fat metabolism pathway and deeply explores the regulation of miR-362-5p targeting GAD2 gene on the progression of renal cell carcinoma (RCC). This innovation provides a new perspective and theoretical framework for RCC research, and is expected to open up a new treatment idea, and a systematic research system from clinical samples, cell experiments, molecular detection to animal experiments is constructed.

The application relates to the field of biological medicine, in particular to a human renal clear cell carcinoma high-metastasis cell line, which is classified and named as human renal clear cell carcinoma high-metastasis cell 786O-M2-Luc Homo sapiens, and the preservation number is CCTCC No: C2025339. The renal clear cell carcinoma high-metastasis cell line can be applied to constructing a renal clear cell carcinoma high-metastasis cell model or an animal model. The cell line of the application can form a stable orthotopic tumor in an immunodeficient mouse, can cause distant organ metastasis such as lung metastasis, can express a GFP and Luciferase double-reporting system, and is convenient for in-vitro sorting and in-vivo IVIS imaging tracking. The cell line of the application retains the typical renal cell carcinoma characteristics of 786-O cells in vitro, but has stronger proliferation, migration and invasion capacity, and can be used as a tool model for renal cancer metastasis mechanism research and drug screening.

This invention discloses the application of reagents for detecting REEP protein in the preparation of products for diagnosing prostate cancer, relating to the field of biomedical technology. Through proteomic analysis, ELISA assays, and immunohistochemical analysis of urinary proteins from prostate cancer patients, clear cell renal cell carcinoma patients, urothelial carcinoma patients, and healthy individuals, as well as paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue, urothelial carcinoma tissue, and clear cell renal cell carcinoma tissue, it was found that REEP6 and REEP5 proteins are related to the occurrence and development of prostate cancer and can be used to assist in the diagnosis of prostate cancer. Furthermore, in urinary testing, REEP6 and REEP5 have higher sensitivity compared to PSA, and the three proteins can complement each other, thus helping to improve the diagnostic rate and non-invasive screening capabilities. Research on the relationship between REEP6 and REEP5 proteins and prostate cancer facilitates non-invasive follow-up after treatment and guides medication, thereby improving survival rates.